Home › Research › Getting a diagnosis
Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias
Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O'Keefe G, Ackerman U et al.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011-07-15
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Unlabelled Amyloid imaging with (18)F-labeled radiotracers will allow widespread use, facilitating research, diagnosis, and therapeutic development for Alzheimer disease. The purpose of the study program was to compare cortical amyloid deposition using (18)F-florbetaben and PET in controls and subjects with mild cognitive impairment (MCI), frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies (DLB), vascular dementia (VaD), Parkinson disease (PD), and Alzheimer disease (AD). Methods One hundred nine subjects in 3 clinical studies at Austin Health were reviewed: 32 controls, 20 subjects with MCI, and 30 patients with AD, 11 with FTLD, 7 with DLB, 5 with PD, and 4 with VaD underwent PET after intravenous injection of 300 MBq of (18)F-florbetaben. Standardized uptake value ratios (SUVR) using the cerebellar cortex as a reference region were calculated between 90 and 110 min after injection. Results When compared with the other groups, AD patients demonstrated significantly higher SUVRs (P Conclusion (18)F-florbetaben had high sensitivity for AD, clearly distinguished patients with FTLD from AD, and provided results comparable to those reported with (11)C-Pittsburgh Compound B in a variety of neurodegenerative diseases.
What this study adds
Evidence grade: Low
The record lists 20 participants. This study found that amyloid imaging with (18)F-florbetaben showed high sensitivity for Alzheimer disease and clearly distinguished patients with frontotemporal lobar degeneration from those with Alzheimer disease. It provided results comparable to those reported with (11)C-Pittsburgh Compound B in a variety of neurodegenerative diseases.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Villemagne, V. L., Ong, K., Mulligan, R. S., Holl, G., Pejoska, S., Jones, G., et al. (2011). Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. https://doi.org/10.2967/jnumed.111.089730
Vancouver
Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2011. doi:10.2967/jnumed.111.089730. PMID: 21764791.
BibTeX
@article{villemagne2011-21764791,
author = {Villemagne, V. L. and Ong, K. and Mulligan, R. S. and Holl, G. and Pejoska, S. and Jones, G. and O'Keefe, G. and Ackerman, U. and others},
title = {{Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias}},
journal = {Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
year = {2011},
doi = {10.2967/jnumed.111.089730},
pmid = {21764791},
url = {https://doi.org/10.2967/jnumed.111.089730}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results When compared with the other groups, AD patients demonstrated significantly higher SUVRs (P < 0.0001) in neocortical areas.
Why it matters
This study found that amyloid imaging with (18)F-florbetaben showed high sensitivity for Alzheimer disease and clearly distinguished patients with frontotemporal lobar degeneration from those with Alzheimer disease. It provided results comparable to those reported with (11)C-Pittsburgh Compound B in a variety of neurodegenerative diseases.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Participants20
- Evidence strengthLow
How this study scored 54/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of nuclear medicine : official publication, Society of Nuclear Medicine) |
| Journal's citation record | 2 / 4 | Journal of Nuclear Medicine: journal h-index 230 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2011 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 20 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 373 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 21.9 citations a year over 17 year(s) since 2011 |
| Impact for its field and year | 4 / 6 | Cited 18.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 31 other studies in this library |
| Still being cited | 2 / 4 | Cited 42 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Christopher Cleon Rowe: h-index 100 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Melbourne: institution h-index 1,342 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 21764791) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.2967/jnumed.111.089730
- PubMed: 21764791
- Original source →
- Free full text: Journal of Nuclear Medicine →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 28.
Later studies that cite this one
31 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Getting a diagnosis from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.